Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117044 | 0.91 | ADORA2A (0.46) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL3118030 | 0.89 | TP53 (0.52) | ADORA1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL13248163 | 0.88 | ADORA1 (0.45) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL13248178 | 0.87 | ADORA2A (0.46) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL3111070 | 0.86 | KDM4E (0.51) | ADORA2BADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL3108609 | 0.85 | HPGD (0.53) | ADORA2BADORA2AADORA1HPGD | |
| SCHEMBL3110193 | 0.85 | HPGD (0.50) | ADORA2BADORA2AADORA1ADORA3HPGD | |
| SCHEMBL3106292 | 0.85 | ADORA2B (0.48) | ADORA2BADORA2AADORA1ADORA3ALDH1A1 | |
| SCHEMBL3108428 | 0.84 | ADORA2B (0.48) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL3119797 | 0.84 | ADORA2B (0.54) | ADORA2BADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | ADORA2B 111/4885ADORA2A 17/4885ADORA1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.